51 related articles for article (PubMed ID: 12960140)
21. Beyond chemotherapy: targeted therapies in ovarian cancer.
Yap TA; Carden CP; Kaye SB
Nat Rev Cancer; 2009 Mar; 9(3):167-81. PubMed ID: 19238149
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.
Fischer H; Taylor N; Allerstorfer S; Grusch M; Sonvilla G; Holzmann K; Setinek U; Elbling L; Cantonati H; Grasl-Kraupp B; Gauglhofer C; Marian B; Micksche M; Berger W
Mol Cancer Ther; 2008 Oct; 7(10):3408-19. PubMed ID: 18852144
[TBL] [Abstract][Full Text] [Related]
23. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.
Sennino B; Falcón BL; McCauley D; Le T; McCauley T; Kurz JC; Haskell A; Epstein DM; McDonald DM
Cancer Res; 2007 Aug; 67(15):7358-67. PubMed ID: 17671206
[TBL] [Abstract][Full Text] [Related]
24. FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod.
Hung IH; Yu K; Lavine KJ; Ornitz DM
Dev Biol; 2007 Jul; 307(2):300-13. PubMed ID: 17544391
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
Klenke FM; Abdollahi A; Bertl E; Gebhard MM; Ewerbeck V; Huber PE; Sckell A
BMC Cancer; 2007 Mar; 7():49. PubMed ID: 17367541
[TBL] [Abstract][Full Text] [Related]
26. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
28. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
29. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
30. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
[TBL] [Abstract][Full Text] [Related]
31. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
32. Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Sahade M; Caparelli F; Hoff PM
Future Oncol; 2012 Jul; 8(7):775-81. PubMed ID: 22830398
[TBL] [Abstract][Full Text] [Related]
33. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Smolle E; Taucher V; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
